Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Rapport Therapeutics (RAPP) Non Operating Income (2023 - 2026)

Rapport Therapeutics (RAPP) has 4 years of Non Operating Income data on record, last reported at $4.4 million in Q1 2026.

  • On a quarterly basis, Non Operating Income rose 43.12% to $4.4 million in Q1 2026 year-over-year; TTM through Mar 2026 was $14.9 million, a 11.68% increase, with the full-year FY2025 number at $13.6 million, up 186.77% from a year prior.
  • Non Operating Income reached $4.4 million in Q1 2026 per RAPP's latest filing, down from $4.7 million in the prior quarter.
  • Over the last five years, Non Operating Income for RAPP hit a ceiling of $4.7 million in Q4 2025 and a floor of -$5.6 million in Q1 2024.
  • A 4-year average of $2.1 million and a median of $2.9 million in 2025 define the central range for Non Operating Income.
  • Peak YoY movement for Non Operating Income: surged 1112.22% in 2024, then dropped 25.4% in 2025.
  • Tracing RAPP's Non Operating Income over 4 years: stood at $1.3 million in 2023, then surged by 176.42% to $3.5 million in 2024, then skyrocketed by 34.03% to $4.7 million in 2025, then decreased by 8.18% to $4.4 million in 2026.
  • Business Quant data shows Non Operating Income for RAPP at $4.4 million in Q1 2026, $4.7 million in Q4 2025, and $3.1 million in Q3 2025.